【ChiCTR2400087923】The efficacy of an online exercise intervention for improving depressive symptoms among patients with subthreshold depression in primary care: a randomized controlled trial
ChiCTR2400087923
尚未开始
/
/
/
2024-08-07
/
/
Subthreshold depression
The efficacy of an online exercise intervention for improving depressive symptoms among patients with subthreshold depression in primary care: a randomized controlled trial
The efficacy of an online exercise intervention for improving depressive symptoms among patients with subthreshold depression in primary care: a randomized controlled trial
1. Examine the effectiveness of a 12-week online instructor-led exercise intervention (EIM) when compared to usual care control in reducing depressive symptoms among people with subthreshold depression in primary care 2. Examine the effectiveness of a 12-week online instructor-led exercise intervention (EIM) when compared to usual care control in reducing anxiety symptoms and improving quality of life among people with subthreshold depression in primary care
随机平行对照
探索性研究/预试验
Stratified block randomization with random block sizes will be used to enhance balance of gender, anxiety symptoms and level of physical activity at baseline between two arms. The randomisation sequence will be generated by an experienced independent statistician using Random Allocation Software. The sealed randomization code will be stored safely and will be inaccessible to any person involved in the study. The randomization number will not be decoded until the participant is assigned to its corresponding randomization number.
The allocation is concealed from the researchers, research assistants or coordinators who carry out the baseline assessment or recorded the data, and the statistician who carries out the analysis.
Health Services Research Fund
/
130
/
2024-07-01
2027-07-01
/
The inclusion criteria for this study are 1) aged 18 years or above; 2) screened by the Patient Health Questionnaire depression scale (PHQ-9) with results categorized as subthreshold depression, major depression or no depression.;
请登录查看The exclusion criteria are 1) dysthymia with subthreshold depressive symptoms that last for 2 years or more; 2) major depression within the past 6 months, lifetime history of psychosis, schizophrenia and bipolar affective disorder, alcohol or substance abuse, presence of serious suicidal risk and medical illness with a prognosis of less than 6 months to live; 3) patients who are taking antidepressants need to be taking the same medications for more than 3 months with good compliance to be eligible to enroll. 4) patients currently enrolled in any form of psychological interventions for any depressive disorders or symptoms and 5) the presence of physical conditions and include the presence of recently diagnosed or uncontrolled cardiovascular diseases or uncontrolled hypertension, metabolic, vascular or neurological conditions.;
请登录查看Joint Chinese University of Hong Kong
/
Joint Chinese University of Hong Kong的其他临床试验
JC School of Public Health and Primary Care, Chinese University of Hong Kong的其他临床试验
- Personalised Lifestyle Medicine in Mid-life Project
- The efficacy of an online exercise intervention for improving depressive symptoms among patients with subthreshold depression in primary care: a randomized controlled trial
- Effects of Behavioural Activation With Mindfulness and Physical Exercise (BAMPE) on Mental Health: A Randomized Controlled Trial
- Effects of stand-alone mindfulness practices for people with long COVID-19 symptoms: A randomized controlled trial
- 慢性腰背痛症者對靜觀治療的支付意願和偏好
- Online integrated mindfulness-meaning programme for depression and anxiety during COVID-19: A pilot randomized controlled trial
- 專科門診病人經驗調查 2018/19
- 對香港自閉症譜系兒童及其家庭進行正念訓練改善其健康狀况
- 正念认知疗法治疗自杀幸存者预试验
- 兩個临床證據質量評估工具的可靠性比較:隨機對照試驗
- 以社區為基礎的隊列研究 - 使用全自動視網膜圖像分析(ARIA)來評估中風風險與生活方式的關系
- Electroacupuncture and Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Trial in Primary Care Setting
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

